If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.09
Bid: 2.01
Ask: 2.09
Change: 0.015 (0.72%)
Spread: 0.08 (3.98%)
Open: 2.05
High: 2.09
Low: 2.05
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

Wed, 31st Aug 2022 21:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

ImmuPharma PLC - specialist drug discovery and development company - Says US partner for Lupuzor, Avion Pharmaceuticals, yet to meet US Food & Drug Administration. "The company is in close contact with Avion and have been advised that the FDA is experiencing general delays in meeting response dates and that this is not specific to Avion and the Type C meeting for Lupuzor. The company will notify the market as soon as practicable once a response from the FDA has been received," it adds.

----------

IDE Group Holdings PLC - Edinburgh-based network, cloud and IT managed services - Auditors request further time to complete work on firm's 2021 results. "The delay in publication relates to the cumulative impact of Covid, including related staff absences from Covid and the resulting knock on impact on the audit process, as previously announced," it says. Expects release before end of September. Had already delayed results, and was expecting them towards the end of July. Previously notes results are expected to show trading Ebitda of GBP3.0 million, but this could "potentially increase" as a result of various potential non-trading audit adjustments.

----------

Galantas Gold Corp - Northern Ireland-focused gold producer - Closes CAD6.9 million, about USD5.3 million, private placement, after upping fundraising with previously hoping to raise CAD4 million. Sells 14.8 million units at CAD0.45 each and further 506,667 units at same price. Each unit holds one share and one-half share warrant. Each warrant can be exchanged for one share, at CAD0.55, until February 28. "The company intends to use the net proceeds of the upsized offering for exploration and development at the Joshua Target as well as for working capital and general corporate purposes," it has previously said.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Appoints two contractors for the upcoming drilling campaign at the Broken Hill Alliance project's East zone. Drilling expected to begin in fourth quarter, subject to regulatory approval from Australia's NSW resources regulator. Managing Director Dennis Jensen "delighted" with appointment of AllState and FieldCrew.

----------

Phoenix Global Resources PLC - London-based upstream oil and gas company focused on Argentina - Says shareholder holding 2% of issued capital sends letter to firm about "certain claims alleged against the company and other parties." Adds: "The board is taking legal advice in relation to the letter and believes the claims that it alleges to be without merit." Has previously proposed delisting from AIM and the Buenos Aires Stock Exchange, providing a "cash exit opportunity for shareholders" in the process. Major shareholder Mercuria Energy Group Ltd, which holds an 84% stake, proposes purchasing shares at 7.5p each under the exit opportunity, a 25% premium to its closing price on June 25, the day before it discussed a potential delisting with Mercuria. Will hold general meeting on September 1 to gain at least 75% shareholder approval for the delisting and the scheme.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
22 Sep 2020 21:17

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

Read more
11 Sep 2020 14:09

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

Read more
11 Sep 2020 12:17

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

Read more
2 Sep 2020 11:18

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Immupharma Raises GBP6.5 Million In Oversubscribed Placing

Read more
2 Sep 2020 09:25

Immupharma raises £6.5m in oversubscribed placing

(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.

Read more
27 Jul 2020 17:50

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

IN BRIEF: ImmuPharma Partner Avion Submits Request To FDA For Lupuzor

Read more
27 Jul 2020 15:15

ImmuPharma clears 'important' regulatory hurdle for Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.

Read more
11 Jun 2020 16:17

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
11 Jun 2020 13:53

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Immupharma Gets Over USD6 Million Investment From US Healthcare Funds

Read more
14 May 2020 17:13

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

UK TRADING UPDATE SUMMARY: Byotrol Sees Continuation Of Strong Demand

Read more
1 May 2020 09:51

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

ImmuPharma Annual Loss Narrows; Plans "Optimised" Lupuzor Trial

Read more
31 Mar 2020 07:31

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

ImmuPharma Raises GBP1.5 Million Through Share Issue To Fund Expansion

Read more
30 Mar 2020 16:18

ImmuPharma raises ?1.5m to fund development programmes

(Sharecast News) - Drug discovery and development company ImmuPharma announced subscriptions to raise ?1.5m through the issue of 15 million new ordinary shares at a price of 10p each on Monday.

Read more
28 Feb 2020 12:06

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Immupharma Inks Subscription Agreement Amid Incanthera's NEX Float

Read more
6 Feb 2020 15:54

ImmuPharma and Avion to proceed with Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.